Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

ClinicalTrials.gov ID: NCT04890106

Public ClinicalTrials.gov record NCT04890106. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized ( 1:1), Double-Masked, Multi-Center, Two-Treatment, Single-Period, Parallel Design, Mutiple Dose Bioequivalence Study With Clinical End-Point of Bimatoprost Ophthalmic Solution 0.01% of Mankind Pharma Limited With LUMIGAN (Bimatoprost Ophthalmic Solution) 0.01% of Allergan, Inc., in Subjects With Chronic Open-Angle Glaucoma Or Ocular Hypertension in Both Eyes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, double-masked, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost Ophthalmic Solution, 0.01% of Mankind Pharma Limited, India Reference Product - LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% of Allergan, Inc.,

Study identification

NCT ID: NCT04890106
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Mankind Pharma Limited; Industry
Enrollment: 310 participants

Conditions and interventions

Conditions

Glaucoma, Open-Angle

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 1, 2021
Primary completion: Aug 10, 2022
Completion: Aug 10, 2022
Last update posted: Dec 12, 2022

2021 – 2022

United States locations

U.S. sites: 9
U.S. states: 3
U.S. cities: 8

Facility	City	State	ZIP	Site status
CBCC Global Research Site:011	Bakersfield	California	93308	—
CBCC Global Research Site 016	Mission Hills	California	91345	—
CBCC Global Research Site 017	Newport Beach	California	92663	—
CBCC Global Research Site: 012	Newport Beach	California	92663	—
CBCC Global Research Site 013	Pasadena	California	91107	—
CBCC Global Research Site 019	Petaluma	California	94954	—
CBCC Global Research Site 015	San Diego	California	92122	—
CBCC Global Research Site 020	Pembroke Pines	Florida	33029	—
CBCC Global Research Site 018	Houston	Texas	77008	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04890106, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 12, 2022 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04890106 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →